No Data
Citi Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $13
Citi analyst Yigal Nochomovitz maintains $Summit Therapeutics(SMMT.US)$ with a buy rating, and maintains the target price at $13.According to TipRanks data, the analyst has a success rate of 45.3%
Dr. David Krajicek Joins Summit Partners as Executive-in-Residence
LONDON--(BUSINESS WIRE)--Global growth equity investor Summit Partners is delighted to welcome Dr. David Krajicek to the firm's Executive-in-Residence ("EIR") program. In this role, Dr. Krajicek
XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio?QuantumScape Corporation (NYSE:QS) stock jumped 64.34% after the company announced it entered into an
Insiders See US$5.84m Investment In Summit Therapeutics Jump Last Week
Summit Therapeutics Inc. (NASDAQ:SMMT) insiders who purchased shares in the last 12 months were richly rewarded last week. The stock climbed by 18% resulting in a US$920m addition to the company's
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 330,000 shares of
Express News | Summit Therapeutics Appoints Jeff Huber, Transformational Google and Grail Executive, to Its Board of Directors